Notal Vision Inc.
9
0
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients
Role: lead
Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD
Role: lead
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT
Role: lead
ForeseeHome NRich Registry
Role: lead
The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT
Role: lead
Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
Role: lead
Home OCT Fluid Visualization Agreement Study
Role: lead
Single In-Clinic Encounter With the Notal Vision Home OCT
Role: lead
Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.
Role: lead
All 9 trials loaded